Skip to content

Released Nov 7, 2017, after the close

10-Q filed Nov 7, 2017, 38 days after period end · 0001162194-17-000159

Q3 2017 · 10-Q
Revenue$24.75M+11.5% vs Q3 2016+3.5% vs Q2 2017
Net Income-$15.94MN/M vs Q3 2016N/M vs Q2 2017
EPS Diluted-$0.46N/M vs Q3 2016N/M vs Q2 2017
Operating Income-$15,602,000N/M
Operating Cash Flowderived-$7,981,000N/M
Free Cash Flowderived-$8,535,000N/M
Margins · derived
Operating margin-63.0%+20.2 pt vs Q3 2016
Net margin-64.4%+24.7 pt vs Q3 2016

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2017Q3 2016Q3 2015Q3 2014
Revenue$24.75M$22.19M$28.64M$29.64M
Net Income-$15.94M-$19.79M-$9.27M-$13.79M
EPS Diluted-$0.46-$0.68-$0.32-$0.49

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Standard Biotools Inc. · CIK 1162194 · Engraved from SEC EDGAR